Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02498652 · ClinicalTrials.gov registry record · Phase 2
Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects
A Phase 2 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT02498652: Completed Phase 2 study, sponsored by Ardea Biosciences.
NCT02498652 is a Phase 2 study that has completed, run by Ardea Biosciences. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02498652, a Phase 2 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects of RDEA3170 administered in combination with allopurinol compared with allopurinol administered alone in adult subjects with gout.
Primary Outcome
Pharmacodynamics (PD) profile of multiple-dose RDEA3170 administered in combination with allopurinol (Cohort 1)
Interventions
- DRUG allopurinol 300 mg
- DRUG RDEA3170 2.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2015-07-28 |
| Est. Completion | 2016-06-02 |
| Phase | Phase 2 |
What the finished NCT02498652 record still lists
NCT02498652 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 2 interventions - of which allopurinol 300 mg is the first listed.
NCT02498652 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02498652 about?
NCT02498652 is a clinical study titled "Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects". This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects of RDEA3170 administered in combination with allopurinol compared with allopurinol administered alone in adult subjects with gout.
What is the current status of trial NCT02498652?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2015-07-28. Estimated completion is 2016-06-02.
What interventions are being tested in trial NCT02498652?
The interventions under investigation include: allopurinol 300 mg (DRUG), RDEA3170 2.5 mg (DRUG).
Who is sponsoring clinical trial NCT02498652?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02498652's enrollment target sits among peer trials
41 1352nd of 2000 higher than 639 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI